Abstracts tagged "Systems-based Studies"

Abstract Number: 1048 • ACR Convergence 2025
Impact of Hydroxychloroquine Usage on QTc in Veterans with Rheumatic Musculoskeletal Disease
Malika Ibrahim¹, Samuel Good², Victor Tran³, David Chetrit⁴, Michael McClean⁵, Myung Shin Sim⁶, Hannah Kang¹, Jennifer Barton⁷, Meika Fang⁸, Angelo Gaffo⁹, fadi Hage¹⁰, cynthia Jackevicius⁵, Michael Pillinger¹¹, gabriela Schmajuk¹², Jasvinder Singh¹³, Alberta Warner¹⁴, Neal Yaun¹⁵ and John FitzGerald¹⁶, ¹David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ²David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Division of Rheumatology, Los Angeles, CA, ³David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Costa Mesa, CA, ⁴Carolina Health Specialists, Myrtle Beach, SC, ⁵Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, ⁶West LA VA Medical Center, Los Angeles, ⁷VA Portland Health Care System/OHSU, Portland, OR, ⁸VA Greater Los Angeles/UCLA, Los Angeles, CA, ⁹Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ¹⁰VA Birmingham health care, Birmingham, AL, ¹¹New York University Grossman School of Medicine, New York,, NY, ¹²University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ¹³Baylor College of Medicine, Houston, TX, ¹⁴VA Greater Los Angeles/UCLA, Los Angeles, ¹⁵UCSF / SFVA, San Francisco, ¹⁶UCLA, Los Angeles, CA
Background/Purpose: Hydroxychloroquine (HCQ) is widely used for rheumatic diseases, but data on its cardiac safety, particularly QTc prolongation, remains limited. Concerns about HCQ inducing QTc…
Abstract Number: 0994 • ACR Convergence 2025
UTAA91: An Off-the-Shelf Allogeneic CAR-Vδ1T Therapy Leveraging CD19 Nanoantibody for B-cell Depletion and PD-1 Agonist Nanoantibody for Pathogenic T-cell Elimination in Refractory Autoimmune Diseases
Licui Jiang¹, Fengtao you¹, Kunmin Yan¹, Jianan Yao¹, Hai Wu¹, Jian Wu², Xin Chang², Cheng Peng², Huimin Meng¹, Min Wang³, Ping Zhang³, Bozhen Zhang⁴ and Lin Yang⁵, ¹PersonGen BioTherapeutics(Suzhou) Co., Ltd., Suzhou, China,, Suzhou, China (People's Republic), ²The First Affiliated Hospital of Soochow University, Suzhou, China (People's Republic), ³PersonGenAnke Cellular Therapeutics Co., Ltd.,Hefei, China,, Suzhou, China (People's Republic), ⁴PersonGen BioTherapeutics(Suzhou) Co., Ltd., Suzhou, China; PersonGenAnke Cellular Therapeutics Co., Ltd.,Hefei, China,, Suzhou, China (People's Republic), ⁵PersonGen BioTherapeutics(Suzhou) Co., Ltd., Suzhou, China; PersonGenAnke Cellular Therapeutics Co., Ltd.,Hefei, China; Cyrus Tang Medical Institute, Soochow University, Suzhou, Jiangsu, China, Suzhou, China (People's Republic)
Background/Purpose: Current therapies inadequately restore immune homeostasis due to incomplete pathogenic cell clearance and limited multi-lineage targeting. UTAA91 integrates: 1) PD-1 agonist-targeted cytotoxicity: The PD-1…
Abstract Number: 0193 • ACR Convergence 2025
Evaluation of electronic health record and efficiency tool utilization by pediatric subspecialists
Samantha Coss¹, Alison Brittain², Jennifer Lee³, Julie Young¹, Ivana Stojkic¹, John Mahan⁴ and Alysha Taxter⁵, ¹Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's Hospital, Canal Winchester, OH, ³Department of Gastroenterology, Nationwide Children's Hospital, Columbus, OH, ⁴Department of Nephrology, Nationwide Children's Hospital, Columbus, OH, ⁵Nationwide Children's, Columbus, OH
Background/Purpose: Excessive interaction with the electronic health record (EHR) is frequently cited as a common source of physician burnout. The administrative burden and extended documentation…
Abstract Number: 0521 • ACR Convergence 2024
Transcriptome Analysis of Drug Response in a Large Cohort of Immune-Mediated Inflammatory Disease Patients Supports Advanced Combination Therapy in Rheumatoid Arthritis
Ernest Choy¹, Maria López Lasanta², Paloma Vela-Casasempere³, Antonio Fernandez Nebro⁴, Santos Castañeda⁵, Carlos Marras⁶, Jaime Calvo-Alén⁷, Jesus Tornero⁸, Juan Cañete⁹, Eugeni Domènech¹⁰, Javier Gisbert¹¹, José Manuel Carrascosa¹², Eduardo Fonseca¹³, Luis Bujanda¹⁴, Valle García¹⁵, Britta Siegmund¹⁶, Giampiero Girolomoni¹⁷, Holger Heyn¹⁸, Pere Santamaria¹⁹, Richard M Myers²⁰, yolanda Guillen²¹, Sergio H Martínez-Mateu²², Sara Marsal²³ and Antonio Julia²⁴, and IMID Consortium, ¹Cardiff University School of Medicine, Cardiff, United Kingdom, ²Hospital Universitari Vall d´Hebron, Rheumatology, Barcelona, Spain, ³Hospital General Universitario Alicante, Alicante, Spain, ⁴Hospital Regional Universitario Carlos Haya , Rheumatology, Málaga, Spain, ⁵Hospital Universitario de la Princesa, Madrid, Spain, ⁶Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, ⁷Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain, ⁸Hospital Universitario de Guadalajara, Guadalajara, Spain, ⁹Hospital Clinic an IDIBAPS, Barcelona, Spain, ¹⁰Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ¹¹Hospital Universitario de la Princesa and IIS-IP, Madrid, Spain, ¹²Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹³Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹⁴Hospital Universitario de Donostia, San Sebastián, Spain, ¹⁵Hospital Universitario Reina Sofía, Córdoba, Spain, ¹⁶Charité – Universitätsmedizin Berlin, Berlin, Germany, ¹⁷University of Verona, Verona, Italy, ¹⁸Centre for Genomic Regulation (CNAG-CRG), National Centre for Genomic Analysis, Barcelona, Spain, ¹⁹Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ²⁰HudsonAlpha Institute for Biotechnology, Huntsville, AL, ²¹Imidomics, Inc, Barcelona, Spain, ²²IMIDOMICs, Barcelona, Spain, ²³Vall Hebron Hospital Research Institute, Barcelona, Spain, ²⁴Vall d'Hebron Hospital Research Institute, Barcelona, Spain
Background/Purpose: Targeted therapies have failed to provide sustained disease remission in most patients suffering from immune-mediated inflammatory diseases (IMIDs). Combining existing drugs could overcome this…
Abstract Number: 0891 • ACR Convergence 2024
Shared and Disease-Specific Mechanisms of Autoimmunity Using Single Cell Sequencing of Peripheral Immune Cells
Jacquelyn Nestor¹, Rachelly Normand¹, Wamia Said¹, Sergio Aguilar², Nandini Samanta¹, Sidney Martin¹, Roya Best¹, Hoang Anh Tran¹, Adrien Antoinette¹, Eilish Dillon³, Devin King³, April Jorge⁴, Maureen Leonard⁴, Pritha Sen³, Kerry Reynolds⁴, John Stone⁵, Michelle Rengarajan¹, Tanuja Chitnis⁶, Kevin Wei⁷, Deepak Rao³, Andrew Luster⁸, Gary Reynolds¹ and Alexandra-Chloe Villani¹, ¹Massachusetts General Hospital, Harvard Medical School, Broad Institute of MIT and Harvard, Boston, MA, ²National Center for Genomic Analysis, Barcelona, Spain, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁶Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁸Massachusetts General Hospital, Charlestown, MA
Background/Purpose: Rheumatologic diseases are characterized by distinct clinical presentations and patterns of organ involvement, yet share many genetic risk factors and treatment responses. This suggests…
Abstract Number: 1431 • ACR Convergence 2024
Computational Systems Biology Approach to Unveil Molecular Interactions in Sjogren’s Disease Pathogenesis
Sacha E Silva Saffar¹, Jacques-Eric Gottenberg², Michele Bombardieri³, Divi Cornec⁴, Jacques-Olivier Pers⁴, Marta Alarcon-Riquelme⁵, Philippe Moigeon⁶, Michael Barnes⁷, Sandra Ng⁸, Wan Fai Ng⁹, Xavier Mariette¹⁰, Gaetane Nocturne¹⁰ and Anna Niaraki¹¹, ¹University Paris Saclay, Le Kremlin Bicetre, France, ²Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ³Centre for Experimental Medicine and Rheumatology, The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ⁴University of Brest, Brest, France, ⁵Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁶Servier Laboratories, France, Gif sur Yvette, France, ⁷William Harvey Research institute, Centre for Translational Bioinformatics, London, United Kingdom, ⁸Centre for Translational Bioinformatics, William Harvey Research Institute, London, United Kingdom, ⁹Department of Rheumatology, Newcastle University, & HRB Clinical Research Facility, University College Cork, Newcastle upon Tyne, United Kingdom, ¹⁰Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ¹¹University of Toulouse, Toulouse, France

Background/Purpose: Sjögren's disease (SjD) presents an unmet medical challenge as there is currently no cure. Despite advances in understanding the immunopathogenesis of SjD, there is…
Abstract Number: 2124 • ACR Convergence 2023
Expansion of Atypical B Cells Accompanies Rheumatoid Arthritis-like Immune Dysregulation in ACPA+ At-risk Individuals
Adam Savage¹, Ziyuan He¹, Marla Glass¹, Julian Reading¹, LauraKay Moss², Marie Feser², Vlad Tsaltskan³, Katherine Nguyen Nguyen³, Kristen Demoruelle², kristine Kuhn⁴, David Boyle³, Cate Speake⁵, Xiao-Jun Li¹, Peter Skene¹, Troy Torgerson¹, Tom Bumol¹, V. Michael Holers⁶, Jane Buckner⁷, Gary Firestein⁸, kevin Deane² and Mark Gillespie¹, ¹Allen Institute for Immunology, Seattle, WA, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of California San Diego, La Jolla, CA, ⁴University of Colorado School of Medicine, Aurora, CO, ⁵Benaroya Research Institute, Seattle, WA, ⁶University of Colorado, Denver, CO, ⁷Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁸University of California San Diego, San Diego, CA
Background/Purpose: Seropositive RA is preceded by an at-risk stage characterized by elevated circulating autoantibodies (AAb), including ACPA, in otherwise healthy individuals without clinically-apparent inflammatory arthritis.…
Abstract Number: 1094 • ACR Convergence 2023
“Lupus Doesn’t Have Me, I Have Lupus” a Patient Centered Quality Improvement Project to Increase Medication Adherence for Patients with Lupus Nephritis
Christopher Macko¹, Patty Chen², Roger Santos³, Nirmala Ramalingam⁴, Nicole Tran⁵ and Sijie Zheng⁶, ¹Kaiser Oakland Internal Medicine Residency, Piedmont, CA, ²Kaiser Oakland Medical Center Department of Rheumatology, Orinda, CA, ³Kaiser East Bay Department of Pharmacy, Oakland, CA, ⁴Kaiser Oakland Medical Center Department of Graduate Medical Education, Oakland, CA, ⁵Kaiser Oakland Department of Adult and Family Medicine, Oakland, CA, ⁶Kaiser Oakland Medical Center Department of Nephrology, Oakland, CA
Background/Purpose: Lupus nephritis (LN) is the most common cause of kidney injury in patients with systemic lupus erythematous (SLE) and is associated with higher morbidity…
Abstract Number: 0077 • ACR Convergence 2022
Rheumatoid Arthritis – Are We Getting to Target?
myint Thway¹, Gurjit S. Kaeley², Karishma Ramsubeik³, Laurie Ramrattan¹, Lilian Otalora Rojas⁴ and Sukhraj Singh¹, ¹University of Florida-Jacksonville, Jacksonville, FL, ²UF COM-J, Ponte Vedra Beach, FL, ³University of Florida, Jacksonville, FL, ⁴University of Florida, Ponte Vedra Beach, FL
Background/Purpose: Low disease activity (LDA) is a key goal in treating Rheumatoid arthritis, but implementing the treat to target approach in clinical practice has been…
Abstract Number: 0329 • ACR Convergence 2022
Scoring Personalized Molecular Portraits Identify Systemic Lupus Erythematosus Subtypes and Predict Individualized Drug Responses, Symptomatology and Disease Progression
Daniel Toro-Domínguez¹, Manuel Martinez-Bueno¹, Raúl López-Domínguez², Jordi Martorell-Marugán¹, Elena Carnero-Montoro¹, Guillermo Barturen¹, Daniel W. Goldman³, Michelle Petri³, Pedro Carmona-Sáez² and Marta Alarcon-Riquelme¹, ¹Center for Genomics and Oncological Research (GENYO), Granada, Spain, ²University of Granada, Granada, Spain, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: Systemic Lupus Erythematosus is a complex autoimmune disease that leads to important worsening of quality of life and mortality. Flares appear unpredictably during the…
Abstract Number: 0640 • ACR Convergence 2022
Immune Cell Heterogeneity in Lupus Nephritis Kidneys and Its Relation to Histopathological Features
Arnon Arazi¹, Joseph Mears², Thomas Eisenhaure³, Qian Xiao⁴, Paul Hoover⁴, Deepak Rao⁴, Celine Berthier⁵, Andrea Fava⁶, Siddarth Gurajala⁴, Michael Peters³, Tony Jones³, William Apruzzese⁴, Jennifer Barnas⁷, Richard Furie⁸, Anne Davidson⁹, David Hildeman¹⁰, Judith James¹¹, Joel Guthridge¹¹, Maria Dall'Era¹², David Wofsy¹³, Peter Izmirly¹⁴, H Michael Belmont¹⁵, Robert Clancy¹⁴, Diane Kamen¹⁶, Chaim Putterman¹⁷, Thomas Tuschl¹⁸, Maureen McMahon¹⁹, Jennifer Grossman¹⁹, Kenneth Kalunian²⁰, Michael Weisman²¹, Matthias Kretzler⁵, Michael Brenner²², Jennifer Anolik²³, Michelle Petri²⁴, Jill Buyon¹⁴, Soumya Raychaudhuri⁴, Nir Hacohen³, Betty Diamond⁹ and the Accelerating Medicines Partnership RA/SLE Network³, ¹Feinstein Institutes for Medical Research, Melrose, MA, ²Michigan University, Ann Arbor, MI, ³Broad Institute, Cambridge, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵University of Michigan, Ann Arbor, MI, ⁶Johns Hopkins University, Baltimore, MD, ⁷University of Rochester, Rochester, NY, ⁸Northwell Health, Great Neck, NY, ⁹Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁰Cincinnati Children's Hospital, Cincinnati, OH, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²University of California, Division of Rheumatology, San Francisco, CA, ¹³University of California San Francisco, SF, CA, ¹⁴NYU Grossman School of Medicine, New York, NY, ¹⁵NYU School of Medicine, New York, NY, ¹⁶Medical University of South Carolina, Charleston, SC, ¹⁷Albert Einstein College of Medicine, Bronx, NY, ¹⁸Rockefeller University, New York, NY, ¹⁹University of California Los Angeles, Los Angeles, CA, ²⁰University of California San Diego, La Jolla, CA, ²¹Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ²²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²³University of Rochester Medical Center, Rochester, NY, ²⁴Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) is characterized by considerable variability in its clinical manifestations and histopathological findings. Understanding the cellular and molecular mechanisms underlying this heterogeneity…
Abstract Number: 1139 • ACR Convergence 2022
Molecular Pathways Identified from Risk Alleles Identify Mechanistic Differences in Systemic Lupus Erythematosus Patients of East Asian and European Ancestry
Katherine Owen¹, Kristy Bell², Andrew Price³, Prathyusha Bachali⁴, Hannah Ainsworth⁵, Miranda Marion⁶, Timothy Howard⁵, Carl Langefeld⁷, Nan Shen⁸, Jinoos Yazdany⁹, Maria Dall'Era¹⁰, Amrie Grammer¹¹ and Peter Lipsky³, ¹RILITE, Crozet, VA, ²AMPEL BioSolutions LLC, Charlottesville, VA, ³AMPEL BioSolutions, Charlottesville, VA, ⁴AMPEL BioSolutions, Redmond, WA, ⁵Wake Forest School of Medicine, Winston-Salem, NC, ⁶Wake Forest University, Winston-Salem, NC, ⁷Wake Forest School of Medicine, Winston Salem, NC, ⁸Shanghai Jiang Tong University School of Medicine, Shanghai, China, ⁹UCSF, San Francisco, CA, ¹⁰University of California, Division of Rheumatology, San Francisco, CA, ¹¹AMPEL LLC, Charlottesville, VA
Background/Purpose: SLE is a multi-organ autoimmune disorder with a prominent genetic component. Individuals of Asian-Ancestry (AsA) disproportionately experience more severe SLE compared to individuals of…
Abstract Number: 0107 • ACR Convergence 2021
Acceptability of the COVID-19 Vaccine in Patients with Rheumatic Diseases and Healthcare Professionals in 19 Arab Countries
Lina El Kibbi¹, Mona Metawee¹, Ihsane Hmamouchi², Nizar Abdulateef³, Hussein Halabi⁴, Mervat Eissa⁵, Manal El Rakawi⁶, Basel Masri⁷, Fatemah Abutiban⁸, Wafa Hamdi⁹, Asal Adnan³, Antonella Abi Najm¹⁰, Renaud Felten¹¹, Laurent Arnaud¹¹ and Nelly Ziade¹², ¹Specialized Medical Center, Riyadh, Saudi Arabia, ²Rheumatology Unit, Temara Hospital, Laboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco, ³Rheumatology Unit, Department of Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq, ⁴King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, ⁵Cairo University, Cairo, Egypt, Cairo, Egypt, ⁶Rheumatology Department, Douera Hospital, Faculty of Medicine, Saad Dahlab, Blida, Algeria, ⁷Jordan Hospital, Amman, Jordan, ⁸Rheumatology Unit, Department of Medicine, Jaber Alahmed Alsabah Hospital, Kuwait City, Kuwait, ⁹Rheumatology Department, Kassab Institute of Orthopedics, UR17SP04, Faculty of Medicine of Tunis, Tunis El Manar University, Tunis, Tunisia, ¹⁰Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon, ¹¹Department of Rheumatology, French National Reference Center for Autoimmune Diseases (CRMR RESO), Strasbourg, France, ¹²Rheumatology Department, Saint-Joseph Medical University and Hotel-Dieu de France Hospital, Beirut, Lebanon
Background/Purpose: The first COVID-19 vaccines were authorized in December 2020. However, their acceptability remains debated and has never been evaluated in patients with chronic rheumatic…
Abstract Number: 0523 • ACR Convergence 2021
Transcriptional Subsetting of SLE Patient Cohorts Based on Metabolic Pathway Activity
Diogo Camacho, Jennifer Swantek, Keng Soh, Jurre Kamphorst, Vivek Kaimal, John Monroe and Edward Driggers, Rheos Medicines, Inc, Cambridge, MA
Background/Purpose: Systemic lupus erythematosus is a highly complex, heterogeneous, autoimmune disorder, with diverse clinical presentation and innate and adaptive immune system involvement. There is a…
Abstract Number: 1061 • ACR Convergence 2021
Comparing Consultation Patterns Across Telehealth Platforms and Face-to-Face Clinic in the Military Health System
Michael Loncharich, David DeSena, Angelique Collamer and Jess Edison, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose: Rheumatic diseases are often diagnostically challenging not only due to rarity, but also because symptoms can develop piecemeal before the diagnosis is clear. Access…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].